The treatment challenges of an exceedingly rare diagnosis of rectal small cell neuroendocrine carcinoma: a case report

Authors

  • Lithira R. Walisinghe Department of Surgery, Ipswich Hospital, Ipswich, Queensland, Australia; School of Medicine and Dentistry, Griffith University, Southport, Queensland, Australia
  • Frana-Katica Batistic School of Medicine and Dentistry, Griffith University, Southport, Queensland, Australia https://orcid.org/0000-0002-0614-0819
  • Jennifer Borowsky Department of Anatomical Pathology, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia https://orcid.org/0000-0003-3957-1364
  • Raphael Varghese School of Medicine and Dentistry, Griffith University, Southport, Queensland, Australia

DOI:

https://doi.org/10.18203/2349-2902.isj20263865

Keywords:

Rectal cancer, Rectal small cell neuroendocrine carcinoma, Colorectal surgery, Radiotherapy, Chemotherapy

Abstract

Small cell neuroendocrine carcinoma (SCNEC) of the rectum is a rare, aggressive malignancy with limited evidence guiding management. We report a case of T4N1b rectal SCNEC in a female presenting with severe proctalgia. Imaging and endoscopy identified a near-obstructing rectal mass, with histology confirming SCNEC. Staging demonstrated locoregional disease without distant metastases. Initial management with platinum-based chemotherapy, etoposide, and radiotherapy achieved partial response; however, persistent disease abutting the posterior vaginal wall necessitated abdominoperineal resection (APR) with partial vaginectomy. Histology revealed poor treatment response and close margins, indicating high recurrence risk. She underwent close surveillance, ultimately progressing to metastatic disease 8 months later, and underwent further adjuvant chemotherapy and immunotherapy. She was eventually palliated with continued deterioration secondary to febrile neutropaenia and myelodysplastic syndrome, ultimately passing away a further 2 months later.  This case highlights the aggressive nature of rectal SCNEC, uncertainty surrounding optimal management, and the need for flexible, multidisciplinary approaches. Further research is required to establish evidence-based disease specific treatment algorithms for a diagnosis that is void of such definitive guidelines and treatment strategies which are largely extrapolated.

References

Antelo G, Hierro C, Fernández JP, Baena E, Bugés C, Layos L, et al. Rectal neuroendocrine carcinoma: case report of a rare entity and perspective review of promising agents. Drugs Context. 2020;15(9):2-4.

Rinke A, Ambrosini V, Dromain C, Garcia-Carbonero R, Haji A, Koumarianou A, et al. European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for colorectal neuroendocrine tumours. J Neuroendocrinol. 2023;35(6):e13309.

Bernick PE, Klimstra DS, Shia J, Minsky B, Saltz L, Shi W, et al. Neuroendocrine Carcinomas of the Colon and Rectum. Dis Colon Rectum. 2004;47(2):163-9.

Smith JD, Reidy DL, Goodman KA, Shia J, Nash GM. A retrospective review of 126 high-grade neuroendocrine carcinomas of the colon and rectum. Ann Surg Oncol. 2014;21(9):2956-62.

Morken S, Langer SW, Hjortland GO, Sundlöv A, Hofsli E, Ladekarl M, et al. Molecular–clinical characteristics and treatment outcomes in 163 metastatic colorectal neuroendocrine carcinomas with a comparison to colorectal adenocarcinomas. Int J Cancer. 2026;158(12):3217-31.

Aytac E, Ozdemir Y, Ozuner G. Long term outcomes of neuroendocrine carcinomas (high-grade neuroendocrine tumors) of the colon, rectum, and anal canal. J Visc Surg. 2014;151(1):3-7.

Sorbye H, Grande E, Pavel M, Tesselaar M, Fazio N, Reed NS, et al. European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma. J Neuroendocrinol. 2023;35(3):e13249.

Clinical Oncology Society of Australia. COSA Neuroendocrine Neoplasms (NENs) Consensus Guidelines. Sydney: Cancer Council Australia, 2022;1-159. Available at: https://files.magicapp.org/guideline/b3c0c2ce-643c-40a7-917c-4ed1489b0b3d/published_guideline_7724-1_0.pdf. Accessed on 20 April 2026.

Shafqat H, Ali S, Salhab M, Olszewski AJ. Survival of patients with neuroendocrine carcinoma of the colon and rectum: a population-based analysis. Dis Colon Rectum. 2015;58(3):294-303.

Brieau B, Lepère C, Walter T, Lecomte T, Guimbaud R, Manfredi S, et al. Radiochemotherapy versus surgery in nonmetastatic anorectal neuroendocrine carcinoma: a multicenter study by the Association des Gastro-Entérologues Oncologues. Medicine. 2015;94(42):e1864.

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Occult Primary (Cancer of Unknown Primary [CUP]). Version 2.2026. Plymouth Meeting (PA): National Comprehensive Cancer Network. 2026;1-86.

Ma YB, Wang ZJ. Current advances in neuroendocrine neoplasms of the colon and rectum. World J Clin Oncol. 2025;16(8):108906.

Ueberroth BE, Liu AJ, Starr JS, Hobday TJ, Ashman JB, Mishra N, et al. Neuroendocrine carcinoma of the anus and rectum: patient characteristics and treatment options. Clin Colorectal Cancer. 2021;20(2):e139-49.

Liu X, Li J, Benish F, Li S, Zhang W. Radiotherapy versus no radiotherapy for rectal neuroendocrine carcinoma patients treated with surgery and chemotherapy: a population-based cohort study. Discov Oncol. 2025;16(1):1559.

Downloads

Published

2026-10-27

How to Cite

Walisinghe, L. R., Batistic, F.-K., Borowsky, J., & Varghese, R. (2026). The treatment challenges of an exceedingly rare diagnosis of rectal small cell neuroendocrine carcinoma: a case report. International Surgery Journal, 13(11), 2271–2277. https://doi.org/10.18203/2349-2902.isj20263865

Issue

Section

Case Reports